The role of the gut microbiome in immune modulation: implications for autoimmune diseases and cancer therapy

The gut microbiome has emerged as a powerful regulator of immune function, profoundly influencing both autoimmune diseases and cancer therapies. Recent advances in microbiome research have unveiled the dynamic interplay between microbial communities and host immunity, revealing how microbial metabolites, bacterial surface molecules, and host-microbe interactions shape immune responses. This review explores the intricate mechanisms by which gut microbiota modulate immune tolerance, inflammation, and cancer immunosurveillance, highlighting the potential of microbiome-targeted interventions. Emerging therapeutic strategies, including fecal microbiota transplantation, engineered probiotics, and microbiome-derived metabolites, offer novel avenues for modulating immune dysfunction and enhancing treatment efficacy. Furthermore, artificial intelligence-driven microbiome profiling and CRISPR-based microbiome engineering hold promise for precision medicine, allowing personalized modulation of microbial ecosystems. Despite these breakthroughs, challenges such as interindividual microbiome variability, mechanistic gaps, and regulatory hurdles continue to impede clinical translation. Addressing these barriers will be crucial to unlocking the full potential of microbiome-based therapies in immune modulation, autoimmunity, and oncology. By integrating multi-omics approaches and advancing microbial therapeutics, the gut microbiome may soon transition from an adjunct to a cornerstone of precision medicine.